ATE487137T1 - Trennung von konjugierten und unkonjugierten sacchariden mittels festphasenextraktion - Google Patents

Trennung von konjugierten und unkonjugierten sacchariden mittels festphasenextraktion

Info

Publication number
ATE487137T1
ATE487137T1 AT05718447T AT05718447T ATE487137T1 AT E487137 T1 ATE487137 T1 AT E487137T1 AT 05718447 T AT05718447 T AT 05718447T AT 05718447 T AT05718447 T AT 05718447T AT E487137 T1 ATE487137 T1 AT E487137T1
Authority
AT
Austria
Prior art keywords
conjugated
saccharide
serogroup
separation
solid phase
Prior art date
Application number
AT05718447T
Other languages
English (en)
Inventor
Angela Bardotti
Daniela Proietti
Stefano Ricci
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32117883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE487137(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE487137T1 publication Critical patent/ATE487137T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)
AT05718447T 2004-03-17 2005-03-17 Trennung von konjugierten und unkonjugierten sacchariden mittels festphasenextraktion ATE487137T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0406013.3A GB0406013D0 (en) 2004-03-17 2004-03-17 Analysis of saccharide vaccines without interference
PCT/IB2005/000987 WO2005090986A2 (en) 2004-03-17 2005-03-17 Analysis of saccharide vaccines without interference

Publications (1)

Publication Number Publication Date
ATE487137T1 true ATE487137T1 (de) 2010-11-15

Family

ID=32117883

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05718447T ATE487137T1 (de) 2004-03-17 2005-03-17 Trennung von konjugierten und unkonjugierten sacchariden mittels festphasenextraktion
AT05718410T ATE500510T1 (de) 2004-03-17 2005-03-17 Trennung von konjugierten und unkonjugierten sacchariden mittels festphasenextraktion

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05718410T ATE500510T1 (de) 2004-03-17 2005-03-17 Trennung von konjugierten und unkonjugierten sacchariden mittels festphasenextraktion

Country Status (18)

Country Link
US (3) US20080305126A1 (de)
EP (4) EP2290366A1 (de)
JP (2) JP4692852B2 (de)
CN (1) CN1981195B (de)
AT (2) ATE487137T1 (de)
AU (2) AU2005224459B2 (de)
BR (1) BRPI0508890A (de)
CA (1) CA2560224C (de)
CY (1) CY1111272T1 (de)
DE (2) DE602005026635D1 (de)
ES (1) ES2353701T3 (de)
GB (1) GB0406013D0 (de)
NZ (2) NZ549907A (de)
PL (1) PL1725872T3 (de)
PT (1) PT1725872E (de)
RU (1) RU2371725C2 (de)
SI (1) SI1725872T1 (de)
WO (2) WO2005090986A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0411387D0 (en) * 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0524782D0 (en) * 2005-12-05 2006-01-11 Chiron Srl Analysis of samples
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US8797995B2 (en) * 2007-01-18 2014-08-05 Cisco Technology, Inc. Device-assisted layer 3 handoff for mobile services
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
US8207298B2 (en) * 2008-05-01 2012-06-26 Archemix Corp. Methods of separating biopolymer conjugated molecules from unconjugated molecules
TW201009337A (en) * 2008-05-30 2010-03-01 Intervet Int Bv Analytical method to monitor vaccine potency and stability
US20100098021A1 (en) * 2008-10-16 2010-04-22 Cisco Technology, Inc. Policy-driven layer 3 handoff for mobile services
US20110223192A1 (en) * 2010-03-10 2011-09-15 Inovobiologic, Inc. Methods for delaying the onset and/or reducing the severity of metabolic syndrome
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
EP2852414B9 (de) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Meningokokken-serogruppe-x-konjugat
CN102735809B (zh) * 2012-06-29 2015-04-29 成都欧林生物科技股份有限公司 测定Hib结合疫苗中高分子结合物含量的方法
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
EP4098276A1 (de) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis-zusammensetzungen und verfahren dafür
CZ2014451A3 (cs) 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CZ309295B6 (cs) 2015-03-09 2022-08-10 Contipro A.S. Samonosný, biodegradabilní film na bázi hydrofobizované kyseliny hyaluronové, způsob jeho přípravy a použití
CZ2015398A3 (cs) 2015-06-15 2017-02-08 Contipro A.S. Způsob síťování polysacharidů s využitím fotolabilních chránicích skupin
CZ306662B6 (cs) 2015-06-26 2017-04-26 Contipro A.S. Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití
CZ308106B6 (cs) 2016-06-27 2020-01-08 Contipro A.S. Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
JP7546566B2 (ja) 2018-08-06 2024-09-06 ニールセン、バイオサイエンシズ、インコーポレイテッド 疣贅の治療
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021064748A1 (en) 2019-10-01 2021-04-08 Biological E Limited Methods for quantification of carbohydrates

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB323103A (en) 1928-12-07 1929-12-24 Fred Cunningham Firth Improvements relating to shaper mechanism for winding yarn on weft bobbins in spinning mules
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (de) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind
FI920131A0 (fi) 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69130136T2 (de) 1990-06-21 1999-03-11 Oxford Glycosciences (Uk) Ltd., Abingdon, Oxon Automatisiertes Verfahren zur Spaltung von Biomolekülen
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
CA2142981C (en) 1992-08-31 2007-10-23 Joseph Y. Tai Vaccines against group c neisseria meningitidis
DE69615362T3 (de) 1995-06-07 2006-07-20 Smithkline Beecham Biologicals S.A. Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2316975C (en) * 1997-12-23 2009-03-24 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
EP1071465A1 (de) 1998-03-18 2001-01-31 Ronai, Peter Amorphe gläser zur stabilisierung von empfindlichen produkten
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
EP1165796A2 (de) 1999-04-09 2002-01-02 Techlab, Inc. Rekombinantes clostridium-toxin a als proteinträger für polysaccharidkonjugatimpstoffen
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
JP5511117B2 (ja) 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のためのワクチン
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP2957300B1 (de) * 2001-01-23 2021-07-14 Sanofi Pasteur Inc. Mehrwertiger meningokokkus-polysaccharid-proteinkonjugat-impfstoff
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN1410532A (zh) * 2002-03-21 2003-04-16 上海凡华生物技术有限公司 一种人/山羊肝嵌合模型的建立及其鉴定方法
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
JP4061960B2 (ja) * 2002-04-26 2008-03-19 株式会社日立製作所 コンピュータシステム
CN1428434A (zh) * 2002-11-14 2003-07-09 中国科学院水生生物研究所 一种检测微囊藻产毒的方法
BRPI0410423A (pt) * 2003-05-07 2006-06-06 Sanofi Pasteur Inc processo de imunogenicidade melhorada para vacinação meningocócica
JP2006528936A (ja) * 2003-05-07 2006-12-28 アヴェンティス パストゥール インコーポレイテッド 多価髄膜炎菌誘導体化多糖−タンパク質複合体およびワクチン
CN102023212B (zh) * 2010-09-28 2014-04-02 汕头大学医学院 一种流感病毒神经氨酸酶抗体的快速检测方法

Also Published As

Publication number Publication date
US8137680B2 (en) 2012-03-20
EP1725871B8 (de) 2011-06-15
AU2011200950A1 (en) 2011-03-24
NZ570193A (en) 2010-02-26
EP1725872A2 (de) 2006-11-29
EP1725871B1 (de) 2011-03-02
EP3035056A1 (de) 2016-06-22
EP1725872B1 (de) 2010-11-03
AU2005224459B2 (en) 2011-02-03
ATE500510T1 (de) 2011-03-15
ES2353701T3 (es) 2011-03-04
BRPI0508890A (pt) 2007-09-11
NZ549907A (en) 2008-10-31
DE602005026635D1 (de) 2011-04-14
WO2005090986A3 (en) 2006-04-13
WO2005090986A2 (en) 2005-09-29
PL1725872T3 (pl) 2011-06-30
CN1981195A (zh) 2007-06-13
JP4692852B2 (ja) 2011-06-01
CY1111272T1 (el) 2015-08-05
CA2560224C (en) 2014-10-21
WO2005090985A1 (en) 2005-09-29
EP1725871A1 (de) 2006-11-29
CA2560224A1 (en) 2005-09-29
US20080286300A1 (en) 2008-11-20
DE602005024523D1 (de) 2010-12-16
JP2007529736A (ja) 2007-10-25
GB0406013D0 (en) 2004-04-21
CN1981195B (zh) 2012-07-04
PT1725872E (pt) 2011-02-08
JP2011013226A (ja) 2011-01-20
US20080305126A1 (en) 2008-12-11
HK1098192A1 (en) 2007-07-13
RU2371725C2 (ru) 2009-10-27
SI1725872T1 (sl) 2011-03-31
US20120171241A1 (en) 2012-07-05
EP2290366A1 (de) 2011-03-02
RU2006136270A (ru) 2008-04-27
AU2005224459A1 (en) 2005-09-29
EP1725872B8 (de) 2011-04-20

Similar Documents

Publication Publication Date Title
ATE500510T1 (de) Trennung von konjugierten und unkonjugierten sacchariden mittels festphasenextraktion
EP2277537A3 (de) Kombiniert Neisseria meningitidis Konjugatsimpfstoff
RU2007102016A (ru) Пространственный анализ конъюгатов сахаридов с помощью gpc и sec-mals
MA30071B1 (fr) Vaccin
WO2003094834A3 (en) Mucosal vaccines with chitosan adjuvant and meningococcal antigens
WO2006067632A3 (en) Saccharide conjugate vaccines
GEP20053691B (en) Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine
ATE552844T1 (de) Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
ATE545659T1 (de) Hypo- und hyperacetylierte meningokokken- kapselsaccharide
RU2006140958A (ru) Иммунизация против менингококков серогруппы y с помощью белков
ATE455793T1 (de) Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
EP2308505A3 (de) Mehrfachimpfstoff einschließlich Meningokokken der Serogruppe C
CY1109582T1 (el) Συνδυασμενα μηνιγγοκοκκινα συζευγματα με κοινη πρωτεϊνη φορεα
PE20070499A1 (es) Composicion inmunogenica
HUP0301413A1 (hu) Vakcinakészítmények
DE60041981D1 (de) Neisseria meningitidis-serumgruppen b und c-antigene sowie ein zusätzliches antigen enthaltende zusammensetzungen
WO2005105140A3 (en) Meningococcal conjugate vaccination
ATE401341T1 (de) Vakzine enthaltend omp85 proteine von neisseria gonorrhoeae und neisseria meningitidis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1725872

Country of ref document: EP